세계의 항염증 치료제 시장 보고서(2025년)
Anti-Inflammatory Therapeutics Global Market Report 2025
상품코드 : 1815679
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

항염증 치료제 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 2029년에 연평균 성장률(CAGR)은 4.9%를 나타낼 것으로 예측되고 1,421억 5,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 혁신적인 치료법, 증가하는 의료비 지출, 희귀 질환에 주력하는 점, 생물학적 제제 및 바이오시밀러 개발 등에 기인할 수 있습니다. 예측 기간의 주요 동향에는 면역요법의 발전, 의약품 개발 분야의 인공지능(AI) 및 머신 러닝(ML) 활용 확대, 적응증 확대 등이 포함됩니다.

향후 5년간 4.9% 성장 전망은 이전 예측 대비 0.1% 소폭 하향 조정된 수치입니다. 이 같은 하향 조정은 주로 미국과 타국 간 관세 영향에 기인합니다. 관세 장벽은 한국과 스위스에서 원산지인 아달리무맙 바이오시밀러와 같은 생물학적 질병 개질 항류마티스 의약품의 비용을 증가시켜 미국 류마티스학 센터의 운영을 저해할 것으로 예상됩니다. 이는 자가면역 질환 치료 접근성을 제한하고 전문의약품 비용을 상승시킬 것입니다. 또한 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 효과가 더 광범위하게 나타날 것입니다.

염증성 장질환(IBD)의 증가하는 발병률은 항염증 치료 시장을 촉진할 전망입니다. IBD는 위장관 염증이 특징인 만성 질환입니다. 항염증 치료제는 염증 감축, 증상 관리, 수술 가능성 저하에 도움을 주어 크론병 같은 질환 치료에 핵심적인 역할을 합니다. 예를 들어, 옥스퍼드 대학교 출판부(OUP)의 2023년 7월 보고서에 따르면 IBD의 발생률은 인구 10만 명당 10.9명, 유병률은 인구 10만 명당 721명으로 나타났습니다. 따라서 염증성 장질환의 증가하는 유병률은 항염증 치료 시장 성장의 상당한 촉진 요인입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Anti-inflammatory therapeutics are prescription drugs designed to address pain, reduce inflammation, and lower elevated body temperatures. They function as modifiers of the body's immune response and are essential in the management of both acute and chronic conditions such as headaches, painful episodes, as well as sprains and strains.

The primary categories of drug classes used in anti-inflammatory therapeutics encompass nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and anti-inflammatory biologics. Nonsteroidal anti-inflammatory drugs are analgesic medications without opioids that are commonly employed by individuals to alleviate mild physical discomfort. These medications find diverse applications in conditions like arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel diseases, and more. They are available through a range of distribution channels, including retail pharmacies, hospital pharmacies, and online retail platforms.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The anti-inflammatory therapeutics market research report is one of a series of new reports from The Business Research Company that provides anti-inflammatory therapeutics market statistics, including anti-inflammatory therapeutics industry global market size, regional shares, competitors with an anti-inflammatory therapeutics market share, detailed anti-inflammatory therapeutics market segments, market trends and opportunities and any further data you may need to thrive in the anti-inflammatory therapeutics industry. These anti-inflammatory therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-inflammatory therapeutics market size has grown steadily in recent years. It will grow from $114.71 billion in 2024 to $117.28 billion in 2025 at a compound annual growth rate (CAGR) of 2.2%. The growth in the historic period can be attributed to prevalence of chronic diseases, aging population, increased awareness, and government initiatives.

The anti-inflammatory therapeutics market size is expected to see steady growth in the next few years. It will grow to $142.15 billion in 2029 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to innovative therapies, increasing healthcare expenditure, focus on rare diseases, biologics and biosimilars. Major trends in the forecast period include advancements in immunotherapy, artificial intelligence (AI) and machine learning (ML) in drug discovery, expansion of indications.

The forecast of 4.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. rheumatology centers by increasing the cost of biologic disease-modifying antirheumatic drugs like adalimumab biosimilars sourced from South Korea and Switzerland, thereby limiting autoimmune disease treatment accessibility and elevating specialty drug expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing incidence of inflammatory bowel disease is set to drive the expansion of the anti-inflammatory therapeutics market. Inflammatory bowel disease (IBD) is a chronic condition characterized by inflammation in the gastrointestinal tract. Anti-inflammatory therapeutics play a pivotal role in the treatment of conditions like Crohn's disease, as they help reduce inflammation, manage symptoms, and lower the likelihood of surgery. For example, a July 2023 report from Oxford University Press (OUP), the university press of the University of Oxford, indicates that IBD has an incidence of 10.9 per 100,000 person-years and a prevalence of 721 per 100,000 people. Consequently, the rising prevalence of inflammatory bowel disease is a significant driver of growth in the anti-inflammatory therapeutics market.

The increasing prevalence of autoimmune disorders is expected to drive the expansion of the anti-inflammatory therapeutics market in the future. Autoimmune disorders encompass a group of medical conditions where the body's immune system, typically responsible for defending against harmful invaders like bacteria and viruses, erroneously targets and attacks the body's own healthy cells and tissues. The growing prevalence of autoimmune disorders plays a significant role in the increasing demand for anti-inflammatory therapeutics. These therapeutics are frequently employed in the treatment of autoimmune disorders, aiming to reduce inflammation, regulate the overactive immune response, and alleviate the symptoms associated with these conditions. For instance, as reported in January 2022 by the Guardian Media Group, a UK-based media company, it is anticipated that there will be 4 million people in the UK suffering from autoimmune disorders, with a global increase estimated at 3% to 9% annually. Additionally, data from May 2023 from the University of Oxford, a UK-based research university, indicates that autoimmune disorders affect 10% of the world's population. Consequently, the rising prevalence of autoimmune disorders is a driving force behind the growth of the anti-inflammatory therapeutics market.

Prominent companies within the anti-inflammatory therapeutics market are actively introducing innovative drugs as a strategy to enhance their market presence. As an example, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, and Sanofi, a France-based pharmaceutical and healthcare company, jointly introduced Kevzara (sarilumab). This represents the first and only anti-inflammatory biologic designed for adult patients dealing with polymyalgia rheumatic (PMR), an inflammatory rheumatic condition. It is particularly targeted at individuals who either do not respond adequately to corticosteroids or cannot tolerate corticosteroid tapering.

In March 2022, Pfizer Inc., a US-based biopharmaceutical company, completed a $6.7 billion acquisition of Arena Pharmaceuticals. This strategic move by Pfizer is intended to enhance its portfolio in the field of inflammation and immunology therapeutics, with a focus on conditions such as ulcerative colitis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. Arena Pharmaceuticals, a US-based company, specializes in the development of diverse anti-inflammatory drugs for the treatment of various immuno-inflammatory disorders.

Major companies operating in the anti-inflammatory therapeutics market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Cipla Inc., Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd.

North America was the largest region in the anti-inflammatory therapeutics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anti-inflammatory therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-inflammatory therapeutics market consists of sales of Ibuprofen, naproxen, and diclofenac. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Inflammatory Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-inflammatory therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for anti-inflammatory therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anti-inflammatory therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Anti-Inflammatory Therapeutics Market Characteristics

3. Anti-Inflammatory Therapeutics Market Trends And Strategies

4. Anti-Inflammatory Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Anti-Inflammatory Therapeutics Growth Analysis And Strategic Analysis Framework

6. Anti-Inflammatory Therapeutics Market Segmentation

7. Anti-Inflammatory Therapeutics Market Regional And Country Analysis

8. Asia-Pacific Anti-Inflammatory Therapeutics Market

9. China Anti-Inflammatory Therapeutics Market

10. India Anti-Inflammatory Therapeutics Market

11. Japan Anti-Inflammatory Therapeutics Market

12. Australia Anti-Inflammatory Therapeutics Market

13. Indonesia Anti-Inflammatory Therapeutics Market

14. South Korea Anti-Inflammatory Therapeutics Market

15. Western Europe Anti-Inflammatory Therapeutics Market

16. UK Anti-Inflammatory Therapeutics Market

17. Germany Anti-Inflammatory Therapeutics Market

18. France Anti-Inflammatory Therapeutics Market

19. Italy Anti-Inflammatory Therapeutics Market

20. Spain Anti-Inflammatory Therapeutics Market

21. Eastern Europe Anti-Inflammatory Therapeutics Market

22. Russia Anti-Inflammatory Therapeutics Market

23. North America Anti-Inflammatory Therapeutics Market

24. USA Anti-Inflammatory Therapeutics Market

25. Canada Anti-Inflammatory Therapeutics Market

26. South America Anti-Inflammatory Therapeutics Market

27. Brazil Anti-Inflammatory Therapeutics Market

28. Middle East Anti-Inflammatory Therapeutics Market

29. Africa Anti-Inflammatory Therapeutics Market

30. Anti-Inflammatory Therapeutics Market Competitive Landscape And Company Profiles

31. Anti-Inflammatory Therapeutics Market Other Major And Innovative Companies

32. Global Anti-Inflammatory Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-Inflammatory Therapeutics Market

34. Recent Developments In The Anti-Inflammatory Therapeutics Market

35. Anti-Inflammatory Therapeutics Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기